- Lobbying
- gilead AND sciences
Lobbying Arrangements Results for 'Gilead Sciences'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Coverage and reimbursement policy related to HCV and HIV portfolios |
Gilead Sciences, Inc.
|
WALTER CONSULTING | |||
Details Ryan White Care Act Reauthorization; Hepatitis C issues. |
Gilead Sciences, Inc.
|
East End Group | |||
Details Issues related to CAR T; policy issues relating to Medicare inpatient and outpatient reimbursement. |
Gilead Sciences, Inc.
|
GRIFFIN CONSULTING, LLC | |||
Details Education related to HCV and HIV. HIV prevention and PrEP. |
Gilead Sciences
|
10-SQUARE SOLUTIONS | |||
Details H.R. 822, H.R. 1943, H.R. 6114, S-2969 |
GILEAD SCIENCES
|
RUBICON ADVISORS, LLC | |||
Details HIV policy issues, Hepatitis C (HCV) policy & payment issues, PEPFAR, antiviral development |
Gilead Sciences
|
Olsson, Frank, Weeda, Terman & Matz, PC | |||
Details Issues related to regulation of prescription drugs and biologics |
Gilead Sciences, Inc.
|
JEFFREY J. KIMBELL & ASSOCIATES, INC. | |||
Details Assisting client with regulatory hurdles in some developing world countries receiving assistance from the USG |
Gilead Sciences
|
Evertz Group LLC | |||
Details H.R.5378 - Lower Costs, More Transparency Act. Education about the 340(b) program. Implementation H.R.5376 - Inflation Reduction Act of 2022. |
Gilead Sciences, Inc.
|
W Strategies, LLC | |||
Details S. 2731, the Tom Lanos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act 2008. All Titles |
GILEAD SCIENCES
|
DCI GROUP, LLC | |||
Details Pending healthcare legislation and potential impact on the biopharmaceutical industry. Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing an... |
GILEAD SCIENCES, INC
|
FOLEY HOAG LLP | |||
Details Provide guidance and strategic counsel with regard to pending healthcare legislation and the potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C pol... |
Gilead Sciences, Inc.
|
BGR Government Affairs | |||
Details Policy issues relating to Medicare inpatient and outpatient reimbursement, including the New Technology Add-on Payment program. |
Gilead Sciences, Inc.
|
BAKER & HOSTETLER LLP | |||
Details Access and reimbursement of drugs in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to reforming and i... |
Gilead Sciences, Inc.
|
THE MCMANUS GROUP | |||
Details Legislative services related to corporate and international tax matters. |
Gilead Sciences, Inc.
|
CAPITOL TAX PARTNERS, LLP | |||
Details Inflation Reduction Act. Issues related to Gilead Sciences' drug portfolio. HIV/AIDS funding. HR 235 Triple Negative Breast Cancer Research & Education. 340B. |
Gilead Sciences Inc.
|
Empire Consulting Group | |||
Details Issues related to the taxation of the biopharmaceutical industry including international taxation |
The Washington Tax & Public Policy Group o/b/o Alliance for Biopharma
lobbying firm |
DOMER CONSULTING, LLC | |||
Details Issues related to intellectual property protections for COVID-19 vaccines and treatments. Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation ... |
Gilead Sciences, Inc.
|
Tiber Creek Group | |||
Details Prescription drug payment reform. Supply Chain. Strategic National Stockpile. 340B. |
Gilead Sciences, Inc.
|
Todd Strategy Group | |||
Details Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare a... |
Gilead Sciences, Inc.
|
Forbes-Tate | |||
Details HIV/AIDS testing and treatment, technology transfer and patent rights, and funding. Patient Protection and Affordable Care Act implementation. Hepatitis funding for screening and linkage to care pr... |
Gilead Sciences
|
PODESTA GROUP, INC. | |||
Details Coverage and reimbursement policy for HCV and HIV portfolios. Issues pertaining to the six protected classes. Drug pricing legislation- part D redesign. Issues related to Medicaid drug rebate progr... |
Gilead Sciences Inc.
|
Farragut Partners LLP | |||
Details Monitored issues related to the reimbursement of CAR-T cell therapy. Monitored H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, H.R. 5376, the Build Back Better Act, and H.R. 19/S. 2164, th... |
Gilead Sciences, Inc.
|
THE NICKLES GROUP, LLC | |||
Details Federal budget issues IRA implementation, pharmaceutical access and affordability, 340B, HCV screening, drug pricing and access, HIV, oncology, PAPHA reauthorization, transparency Medicare & Medica... |
Gilead Sciences, Inc.
|
TARPLIN, DOWNS & YOUNG, LLC | |||
Details Issues related to triple negative breast cancer Issues related to HIV Outreach re: Women's Health Research Initiative |
Gilead Sciences, Inc.
|
The Duberstein Group Inc. | |||
Details International trade and protection of intellectual property; TRIPS Waiver; the Medical Supply Chain Resiliency Act; compulsory licensing and other IP issues in multiple countries. Advocate on drug ... |
GILEAD SCIENCES, INC.
|
in-house lobbying | |||
Details General healthcare issues; pandemic related issues; drug pricing issues; PBM reform. |
Gilead Sciences, Inc.
|
AKIN GUMP STRAUSS HAUER & FELD |